REGULATORY EXPECTATIONS AND RISK ASSESSMENT FOR BIOThERAPEUTIC PRODUCTS

Scientific Principles to Consider

NOTE:
This document has been prepared for the purpose of inviting comments and suggestions on the proposals contained therein, which will then be considered by the Expert Committee on Biological Standardization (ECBS). Publication of this early draft is to provide information about the proposed WHO document on Regulatory Expectations and Risk Assessment for Biotherapeutic Products to a broad audience and to improve transparency of the consultation process.

The text in its present form does not necessarily represent an agreed formulation of the Expert Committee. Written comments proposing modifications to this text MUST be received by 12 March 2014 in the Comment Form available separately and should be addressed to the World Health Organization, 1211 Geneva 27, Switzerland, attention: Department of Essential Medicines and Health Products (EMP). Comments may also be submitted electronically to the Responsible Officer: Dr Hye-Na Kang at email: kango@who.int.

The outcome of the deliberations of the Expert Committee will be published in the WHO Technical Report Series. The final agreed formulation of the document will be edited to be in conformity with the "WHO style guide" (WHO/IMD/PUB/04.1).
frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors [or editors as appropriate] alone are responsible for the views expressed in this publication.
# Table of contents

1. Background .............................................................................................................. 4
2. Regulatory Expectations for Biotherapeutic Products ............................................. 4
3. Regulatory Expectations for Copy Products ............................................................ 6
4. Regulatory Evaluation of Similar Biotherapeutic Products ...................................... 7
5. Regulatory Capacity Needs ..................................................................................... 8
6. Risk Assessment Considerations ........................................................................... 9
7. Points to Consider in a Stepwise Risk Based Assessment ........................................ 10
8. Authors and Acknowledgements .......................................................................... 13
9. References .................................................................................................................. 14
**Background**

This document sets out scientific principles to be considered by national regulatory authorities (NRAs) and manufacturers in the process of licensing biotherapeutic products used in human medicine. It covers the regulatory expectations for innovative biotherapeutic products, for so called copy products, as well as for similar biological products. The document also considers the regulatory risk assessment needed for dealing with situations where, for various historical reasons, products were licensed under conditions which did not meet international regulatory expectations for these biologicals as set out in this document, e.g. biotherapeutic products licensed through generic approach/pathway. The International Conference of Drug Regulatory Authorities (ICDRA) discussed such situations at its meeting in Singapore in 2010 (1) and requested the WHO to assist in developing approaches to evaluating these already licensed products according to WHO guidelines or for phasing them out in a reasonable period of time.

Although this document deals primarily with biotherapeutic protein products, some aspects are also relevant to polysaccharide based medicines, such as heparins.

**Regulatory Expectations for Biotherapeutic Products**

Special considerations apply to the production and control of biological medicines, including biotherapeutics, which do not apply to chemical drugs. This is because of the biological nature of the starting materials, the manufacturing processes and the test methods needed to characterize batches of the product. For example, production of many biotherapeutics involves the culture of cells and microorganisms. Others, such as heparins, are isolated directly from biological materials. Also, biologicals are highly complex products in molecular terms, sometimes derived using recombinant DNA techniques. Even with the great progress made in the ability to purify and characterize biologically active macromolecules with respect to their protein, lipid and oligosaccharide components, it is still not possible to fully predict their biological properties and clinical performance from their physicochemical characteristics alone. Nonclinical and clinical evaluation are therefore key components of the regulatory assessment of such biotherapeutics.
Furthermore, biological systems are known to be inherently variable, a feature which has important consequences for the safety and efficacy of the resulting product. Although comprehensive analytical characterization of the drug substance and/or drug product is expected, considerable emphasis must also be given to the manufacturing process, including process validation and in-process control. Understanding the production process and monitoring consistency of production are, therefore, critical since slight variations in the manufacturing process can impact the clinical safety and efficacy of the product and occasionally lead to major adverse effects, such as immunogenicity, with potentially serious safety implications. The demonstration that batches of product do not differ from those of lots shown to be safe and effective in clinical studies is a crucial component not only of product evaluation and licensing but also of on-going regulatory oversight.

Regulatory expectations for biotherapeutic protein products can be found in the WHO Guidelines on the Quality, Safety and Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA Technology which were adopted by the WHO Expert Committee on Biological Standardization at its meeting in October 2013 (2). These extensive guidelines provide NRAs and manufacturers with guidance on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology and intended for use in humans. They are based on over three decades of experience in this technically demanding field and replace “Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology” (WHO Technical Report Series 814, Annex 3, 59 – 70, 1991). They are the result of several reviews and consultations during the period 2012-2013 and are considered to be a replacement and not a revision of the original WHO guidelines. This is because they contain new sections on nonclinical and clinical evaluation of rDNA-derived protein biotherapeutics which were lacking in the original document. In addition, a section on issues related to manufacturing changes both during development and once the product is on the market also has been introduced. The scope of products covered by these WHO Guidelines includes:

- All biologically active protein products used in the treatment of human diseases and which are prepared by rDNA technology;
- Protein product used for in vivo diagnosis, such as monoclonal antibody products used for imaging and products used for ex vivo treatment;
- Protein products intentionally modified by e.g. pegylation, conjugation with a cytotoxic drug or modification of rDNA sequences.

**Regulatory Expectations for Copy Products**

As patents and data protection measures for innovative biotherapeutic products expire, or near expiration, there has been considerable interest in producing copies of these highly successful medicinal products. Indeed, copies of biotherapeutic protein products have been produced in some developing countries even before patents had expired globally. For example, under trade-related aspects of the Intellectual Property Rights (TRIPS) Agreement of the World Trade Organization, the pre-1995 product patents did not apply in India and this left many biological products that were patented before 1995 marketable in India. Furthermore, innovators have not sought patent protection for some drugs in India thereby creating an opportunity for Indian companies to influence the huge domestic market and to supply other countries where these products had not been patented (3). The emphasis of many Indian pharmaceutical manufacturers has been directed more toward the development of copies rather than original molecules because of much lower development costs including reduced time to market (4).

Much of the interest in this pharmaceutical area has been driven by the possibility that copy products would be more affordable than the innovative ones and thus improve access to much needed biotherapeutic medicines globally. The major question that arose was how copies of the innovator products should be licensed, and whether there could be a reduction in the nonclinical and clinical package submitted, bearing in mind that these medicines are highly complex products, manufactured by equally complex and sophisticated processes, a situation compounded by the inherent problem of biological variability. It was recognized that copying biologicals would be much more complex than copying small molecules. Many biological molecules consist not only of the amino acid sequence but also of various polysaccharides which are added onto the polypeptide backbone during post-translational modification. Changes, such as deamidation, oxidation or N-and C-terminal differences, can also occur in the polypeptide chain. Details vary depending on the production process and may or may not affect clinical performance. Particular attention also needs to be given to the
possible presence of adventitious viruses in biotherapeutics produced in mammalian
cells. Quite clearly some clinical data would be required for licensing such copy
biological products, and quite clearly too, a traditional generic pathway as used for
small molecule drugs would not be appropriate. The concept of “similar but not
identical biological products”, with a designated regulatory pathway, was then
developed by the WHO (5) and other countries, following the lead of the European
Medicines Agency (6).

Regulatory Evaluation of Similar Biotherapeutic Products
Following considerable international consultations at the global level since 2004,
WHO Guidelines on evaluation of similar biotherapeutic products were published in
2010 (5). These rely on a head to head demonstration of the “similarity” of a
candidate biological product’s characteristics, with respect to both physicochemical
and biological activity to a defined and already licensed reference product in order to
justify a reduced non-clinical and clinical package for licensing the candidate product
which is expected to reduce overall development costs and time to market. Critically,
this head to head comparability exercise involves not only evaluation of quality
attributes but also of non-clinical and clinical aspects with the same reference
biological product throughout. The Guidelines emphasize the need for clinical studies
to be designed so as to specifically demonstrate comparable safety, efficacy and
immunogenicity between the products in sensitive populations in order for the
candidate product to be called a similar biotherapeutic product.

These WHO Guidelines are intended to provide a globally acceptable set of basic
principles regarding the evaluation of similar biotherapeutics although it was
recognized that, by themselves, they will not resolve all issues. Several countries or
jurisdictions have now developed their own guidelines but there are some differences
in detail between them. Furthermore, other regulatory pathways, such as a stand-alone
approach, may also be appropriate for licensing copy biologicals (7). However, it was
reaffirmed at a WHO Consultation in Seoul (7, 8) in 2010 that only copy biologicals
licensed on the basis of a full comparability package involving head to head
comparative evaluation of quality, nonclinical and clinical aspects with one defined
reference product should be called similar biological products. It was suggested that
copy products appropriately licensed by other pathways might be called “non-innovative biological products” but this has not yet been universally accepted and several names are being considered. Nevertheless, there is full agreement that the approach to licensing small-molecule generic medicines, involving only product analysis and the demonstration of bioequivalence to a reference product, is not appropriate for the development, evaluation and authorization of copy biological products. As already mentioned above, clinical performance of biologicals is highly dependent on the manufacturing process and slight changes can lead to adverse clinical effects. Some clinical studies are therefore essential to demonstrate the safety and efficacy of copy biological products since it is still not possible to predict biological properties and clinical performance from physicochemical characteristics alone. Consistency of production is also critical since unintentional changes during production may impact product performance.

Regulatory Capacity Needs

Although discussions on how best to license copy biotherapeutics on the basis of a reduced nonclinical and clinical data package continues, there is increasing alignment between jurisdictions on key issues (see 9). Since the publication of the WHO Guidelines on evaluation of similar biotherapeutic products (5), several activities have been undertaken by the WHO at both global and regional levels. It has become clear that much investment in the development of biosimilar and copy biotherapeutic products is taking place worldwide, including in countries with emerging economies. It is also becoming clear that the regulatory agencies of many countries need to be strengthened with respect to their regulatory oversight of biotherapeutic products in general and biosimilars and copy products in particular. The expertise of regulators responsible for licensing is critically important for the appropriate evaluation of these often sophisticated products which should be understood to be biologicals and which may include proteins, polysaccharides and DNA molecules. Regional initiatives to improve the awareness of countries concerning these issues are already well underway in some areas, for example in PAHO (10, 11), but needs may differ from region to region.
Risk Assessment Considerations

A serious problem has been identified in some countries where, for historical reasons, biotherapeutic products have been licensed on data which did not meet international regulatory expectations regarding quality, nonclinical and clinical data. Sometimes, copy products have even been licensed as simple generics (12). Generally, little is known about the safety and efficacy of the individual products, since in most cases pharmacovigilance in the countries concerned is weak. In addition, the nomenclature for these products is confusing and traceability poor (13). In some countries, the coexistence on the market at the same time of inappropriately licensed copy products and true biosimilars is a matter of concern. The lack of terminology for products developed as copy products with only partial comparability to a reference product has compounded the problem and led to a great diversity in evaluating as well as naming these products (8)

Slight differences between the biotherapeutic product of one manufacturer and that of another, or between an innovator and copy biotherapeutic product, could have unintentional effects on their clinical performance and safety and need to be handled carefully from a regulatory perspective. NRAs should consider undertaking a regulatory risk assessment of biotherapeutic products already on the market but known to have been licensed with data which do not meet international regulatory expectations. A risk based approach to dealing with this problem would allow licensed biotherapeutic products to remain on the market for a specified period during which time manufacturers would be required to submit first a Risk Management Plan for regulatory approval and subsequently appropriate quality, nonclinical and clinical data, as necessary, for regulatory evaluation to support the continuation of the license. The timeline for completing such a review exercise would depend on the risk assessment of each individual product on the market. Products from manufacturers who did not submit a Risk Management Plan or appropriate data, or submitted data which were considered insufficient to support continued licensing, would be automatically removed from the market.

In adopting a risk based approach, product supply would not be compromised and authorization would be regularized after the defined time period when all products would have undergone further regulatory evaluation and found to meet internationally accepted standards of quality, safety and efficacy. Should a problem be identified with
a particular product before the end of the specified time period, the implicated product’s license could be withdrawn immediately or the labelling modified as appropriate. A product claimed to be a similar biotherapeutic but failing to meet WHO Guidelines (5) could be given the opportunity to be re-submitted as a stand-alone product or the labelling modified as appropriate.

Traceability is a key element in monitoring the performance of biotherapeutic products since some problems maybe batch related. An adequate nomenclature system is essential to ensure specific identification. This should include not only the International Non-proprietary Name (INN) but also other important indicators such as brand (proprietary) name, manufacturer’s name, country of origin and, critically, the lot number.

Points to Consider in a Stepwise Risk Based Assessment

A stepwise risk-benefit assessment, based on product-specific considerations, should be carried out in order to decide the appropriate action and the time a particular inappropriately licensed product should be allowed to remain on the market prior to finalization of the review. This will depend upon the time needed to generate and provide the missing information, the risk associated with removing the product from the market and the risk of keeping the product on the market, and could be between say 6 months and 4 years. However, manufacturers should first be required to submit a Risk Management Plan to the NRA within a short time period detailing their proposals for dealing with the situation including the generation and provision of quality, non-clinical and clinical data as appropriate. An example of a risk based plan for dealing with a particular regulatory situation can be found in the actions of Health Canada. In 2009, Health Canada initiated a risk based plan of action to deal with changes in the regulatory oversight of heparins to reflect the fact that in future they would be regulated in Canada as biologics and not pharmaceutical drugs. While both unfractionated heparins and low molecular weight heparins are administratively controlled as drugs in some administrations, they are essentially biologicals and the importance of their biological origin is increasingly recognized by the global regulatory community. Health Canada set a 12 month transition period to allow manufacturers to update their files to reflect data required for biological drugs. Manufacturers were also required to identify immediately after the official date of
transfer of regulatory authority how much of their licensed product was sold in
Canada per year. In addition Health Canada announced that any biosimilar heparin
submissions should follow Health Canada’s regulatory framework for subsequent
type biologics and not the generic pathway used for small molecule drugs (14).

Consideration should be given to the following in deciding appropriate actions:

a) The number of inappropriately licensed products on the market and whether
there are any alternatives on the market which have been licensed also by an
experienced NRA (see b, below).

b) Whether the product in question is manufactured and licensed in a country
with a jurisdiction which has well established regulatory frameworks and
principles, as well as considerable experience in the evaluation of
biotherapeutic products, and post marketing surveillance activities. If a
product is manufactured and licensed in such a country, then this provides
confidence regarding its quality, safety and efficacy. However, it would be
important to ascertain whether the product on the market but inappropriately
licensed in the country with limited regulatory experience is identical,
including site of manufacture, to that licensed, supplied and used in the
manufacturing country with the more experienced jurisdiction;

c) The extent to which the registration dossier of the biotherapeutic product
meets the recommendations of the WHO Guidelines on the Quality, Safety and
Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA
Technology and the WHO Guidelines on Evaluation of Similar Biotherapeutic
Products (2, 5). Attention should be paid to any important differences between
national requirements and WHO Guidelines, such as mandatory requirement
for viral validation and human immunogenicity studies and data needed to
allow extrapolation of biosimilars to other indications (4)

d) The level of actual use of the biotherapeutic product in the clinic (market share
or number of patients impacted);

e) Whether the product is essential for treating certain patients. This assessment
should cover: What is the disease being treated?; Is the condition life-
threatening?; What are the consequences of treating or not treating?; What is
the nature of the affected patient population (paediatric, adult, senior/elderly);
f) The expected severity of the consequences of supply problems on clinical outcomes should the product be taken off the market;

g) The seriousness of a potential lack of efficacy, as well as possible safety issues that may result from the continued use of the product under review. This should include an assessment of the severity of the potential impact on a patient of an immunogenic effect arising from the use of the product;

h) The ability of the pharmacovigilance system in place in the country to monitor and determine adverse reactions and/or efficacy problems, such as reduced clinical effectiveness, associated with the biotherapeutic product, should they exist. With poor pharmacovigilance systems in many countries, as well as nomenclature difficulties, it may be impossible to obtain sufficient data to demonstrate that a particular product was the cause of an adverse reaction or that patients may be at risk from the use of clinically inadequate products. Traceability through appropriate labelling is a key element in monitoring the performance of biologicals.

i) As already mentioned, the expertise and capacity of regulators responsible for licensing biotherapeutic products is critically important for the appropriate evaluation of these products. Capacity building will be needed where resources and expertise is considered inadequate. Where the number and experience of persons available to undertake an overall review is limited, consideration could be given to the possible mentoring of the NRA needing support by an experienced authority through the WHO.

j) Consideration should be given to transparency with respect to informing healthcare professionals, pharmacists and patients of the review process and its time lines. This could be done through website posting, as in Canada (14), and referring to the need to align the licensing process with current international expectations.
Authors and Acknowledgement

The first draft of this document was prepared by Dr Elwyn Griffiths, WHO consultant, Kingston-upon-Thames, UK; Dr Hye-Na Kang and Dr Ivana Knezevic, TSN/EMP/HIS, WHO, Geneva, Switzerland.

Comments were received from the following reviewers:

Mrs Arpah Abas, Ministry of Health Malaysia, Selangor, Malaysia; Dr Wesal Salem Alhaqais, Jordan Food and Drug Administration, Amman, Jordan; Nestor Annibali, ALIFAR, Argentina; Mrs Janis Bernat on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland; Dr Boontarika Boonyapiwat, Ministry of Public Health, Nonthaburi, Thailand; Gioconda Castillero, Ministerio de Salud, Panama; José Manuel Cousiño, FIFARMA, Chile; Fabiola Muñoz Espinoza, Agencia Nacional de Medicamentos Instituto Nacional de Salud – Chile; María Teresa Ibarz, INH “RR”, Caracas, Venezuela; Dr Agnes Klein, Health Canada, Ottawa, Canada; Dr Catherine Njue, Health Canada, Ottawa, Canada; Dunia Pérez, INH “RR”, Caracas, Venezuela; Dr G. R. Soni, National Institute of Biologies, Ministry of Health and Family Welfare, Government of India, Noida, India; Mr Hans Vásquez, DIGEMID, Lima, Perú.

The second draft was prepared by the same authors; taking into considerations of comments received from above reviewers as well as the discussion at the 2nd WHO Implementation Workshop on Quality Assessment of Similar Biotherapeutic Products held in Xiamen, China, on 28 May – 30 May 2012, attended by:

Mrs Arpah Abas, Ministry of Health Malaysia, Selangor, Malaysia; Dr Wesal Salem Alhaqais, Jordan Food and Drug Administration, Amman, Jordan; Ms Jennifer Archer, Hospira, Thebarton, Australia, representative of the International Generic Pharmaceutical Alliance (IGPA); Dr Boontarika Boonyapiwat, Ministry of Public Health, Nonthaburi, Thailand; Dr Laura Gomes Castanheira, ANVISA, Brasilia, Brazil; Dr Weihong Chang, State Food and Drug Administration (SFDA), Beijing, China; Dr Ranjan Chakrabarti, United States Pharmacopeia-India, Shameerpet, India, representative of the United State Pharmacopoeial Convention; Mr Dusheng Cheng, Beijing Four Rings Bio-Pharmaceutical Co., Ltd., Beijing, China; Dr Liang Chenggang, National Institutes for Food and Drug Control (NIFDC), Beijing, China; Dr Youngju Choi, Korea Food and Drug Administration (KFDA), Osong, Korea; Ms Juliati Dahlan, National Agency of Drug and Food Control, Jakarta, Indonesia; Mr Geoffrey Eich, Amgen Inc. Corporate Services / Global Regulatory Affairs & Safety, Thousand Oaks, USA, representative of IFPMA; Dr Martin Howell Friede, IER/IEA, WHO, Geneva, Switzerland; Dr Kai Gao, NIFDC, Beijing, China; Mr Thomas Go, Health Sciences Authority (HSA), Helios, Singapore; Dr Elwyn Griffiths, Kingston-upon-Thames, UK; Dr Lawrence Gu, Shenyang Sunshine Pharmaceutical Co. LTD., Shenyang, China; Dr Zhongping Guo, Chinese Pharmacopoeia Commission, Beijing, China, representative of the Chinese Pharmacopoeia; Dr Nazila Hassannia, Biological Office Food and Drug Organization, Tehran, Iran; Dr Kowid Ho, ANSM, France; Dr Simon Hufton, National Institute for Biological Standards and Control, Potters Bar,
UK; Mrs Wichuda Jariyapan, Ministry of Public Health, Nonthaburi, Thailand; Mr Ren Jian, HSA, Helios, Singapore; Dr Jeewon Joung, KFDA, Osong, Korea; Dr Hye-Na Kang, TSN/EMP/HIS, WHO, Geneva, Switzerland; Dr Yasuhiro Kishioka, Pharmaceutical and Medical Devices Agency (PMDA), Tokyo, Japan, representative of the Japanese Pharmacopoeia; Dr Ivana Knezevic, TSN/EMP/HIS, WHO, Geneva, Switzerland; Mr James Leong, HSA, Helios, Singapore; Dr Jing Li, Shanghai CP-Guojian Pharmaceutical Co., Ltd., Shanghai, China; Dr Jianhui Luo, SFDA, Beijing, China; Mrs Vivian Madrigal, Recepta Biopharma, Sao Paulo, Brazil; Dr Catherine Njue, Health Canada, Ottawa, Canada; Mrs Yanet Hechavarria Nunez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba; Dr Pan Huirong Pan, Innovax BIOTECH CO. Ltd., Xiamen, China, representative of the Developing Country Vaccine Manufacturing Network (DCVMN); Dr Rolando Perez, Biotech Pharmaceutical Co., Ltd., Beijing, China; Dr Stefanie Pluschkell, Pfizer Inc., Grotong, USA, representative of the IFPMA; Prof Chunming Rao, NIFDC, Beijing, China; Dr Martin Schiestl, Sandoz GmbH, Kundl/Tirol, Austria, representative of IGPA; Dr Thomas Schreitmueller, F. Hoffmann-La Roche, Ltd. Basel, Switzerland, representative of IFPMA; Dr Satyapal Shani, Ministry of Health and Social Welfare, Government of India, New Delhi, India; Dr Qi Shen, NIFDC Beijing, China; Dr Xinliang Shen, China Bio-Tech Group, Beijing, China; Dr G. R. Soni, National Institute of Biologics, Ministry of Health and Family Welfare, Government of India, Noida, India; Dr Li Sun, Xiamen Amoytop Biotech Co., LTD., Xiamen, China; Dr Robin Thorpe, NIBSC, Potters Bar, UK; Mrs Cornelia Ulm, Mylan GmbH, Zurich, Switzerland, representative of the European Generic medicines Association (EGA); Dr Antonio Vallin, Centre of Molecular Immunology, Habana, Cuba; Dr Jian Wang, Health Canada, Ottawa, Canada; Dr Junzhi Wang, NIFDC, Beijing, China; Dr Miao Xu, NIFDC, Beijing, China; Dr Shumin Zhang, SFDA, Beijing, China.

The draft document is posted on the WHO Biologicals website for the first round of public consultation from 11 February to 12 March 2014.

References


